- The NHS is set to roll out a new monthly injection for eczema sufferers that has been shown to completely banish rashes in four out of five people.
- Lebrikizumab, approved by EU regulators, targets a protein in the body that causes inflammation, providing relief for adults and children over the age of 12 affected by the condition.
- Kymmene Dawson, a patient who struggled with severe eczema for years, saw significant improvements in her skin after starting lebrikizumab, describing it as life-changing.
- More than 5.2 million adults and 2.5 million children in the UK currently suffer from moderate to severe eczema, with the condition often requiring prescription washes, steroid creams, and immunosuppressant drugs as treatment.
- Trials of lebrikizumab have shown promising results, with reduced side effects compared to other treatments and the potential for long-term clear skin for patients with moderate to severe eczema.
Source link
Dermatology,Pulmonary Medicine,Public Health & Prevention